Replimune Group (NASDAQ:REPL) Releases Earnings Results, Beats Expectations By $0.07 EPS

Replimune Group (NASDAQ:REPL) released its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07, Zacks reports.

Replimune Group Stock Performance

NASDAQ REPL opened at $11.40 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 13.46. Replimune Group has a 12-month low of $4.92 and a 12-month high of $12.97. The company has a fifty day simple moving average of $11.44 and a 200 day simple moving average of $9.50.

Analyst Ratings Changes

REPL has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $16.80.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.